Trial
NCT05493293
Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Neurocrine Biosciences
Collaborators
—
Condition
Focal Onset Seizure
Intervention
NBI-921352
Why stopped
The long-term extension study was terminated because the parent study NBI-921352-FOS2021 (NCT05159908) failed to meet its primary endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-04-12